NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma. It has reasonable selectivity for the CB2 receptor subtype having a CB2 affinity of 0.4nM and 25x selectivity over the related CB1 receptor.
This page contains content from the copyrighted Wikipedia article "NESS-040C5"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
